

Bio – Katie Brinkman



As Biocompatibility Program Manager at Hohenstein Medical, Katie Brinkman leads the development and strategic positioning of Hohenstein's medical device biocompatibility program, with a focus on chemical characterization, ISO 18562 gas pathway testing and ethical, non-animal assays. Through her collaborative leadership combined with scientific rigor and regulatory acumen, she helps guide companies to find the specific testing they need for their medical devices.

Katie has more than 15 years of experience in biological sciences. Prior to joining Hohenstein, Katie held senior biocompatibility roles at Cook Research, NAMSA, Abbott and Johnson & Johnson, where she authored numerous biocompatibility and toxicological risk assessment reports supporting global regulatory submissions. Her experience spans the entire medical device lifecycle — from new product development and design changes to EU MDR remediation and post-market evaluations.

Katie holds a Bachelor of Science in Biology from Mississippi University for Women and is an active member of the Society of Toxicology (SOT) and the Regulatory Affairs Professionals Society (RAPS). She is certified as a Biological Safety Specialist by NAMSA and has deep expertise in ISO 10993 and related vertical standards.